Tolerance to melanin-associated antigen in autoimmune uveitis is mediated by CD4+CD25+ T-regulatory cells.
Experimental autoimmune anterior uveitis (EAAU) serves as an animal model for human idiopathic AU, the most common form of intraocular inflammation of significant morbidity whose recurrence can lead to permanent vision loss. This study was undertaken to inhibit EAAU by inducing tolerance to melanin-associated antigen (MAA) and to investigate the underlying mechanisms responsible for tolerance induction. Intravenous administration of MAA both induced tolerance and inhibited EAAU in Lewis rats. Flow cytometric analysis revealed that the proliferation of lymph node cells in response to antigenic stimulation was drastically reduced in the state of tolerance both in vivo and in vitro. Our results from co-culture experiments demonstrated that intravenous administration of MAA led to the generation of T-regulatory cells that suppress T-cell proliferative responses and induce tolerance. Expression levels of both interleukin-10 and transforming growth factor-beta2 were elevated whereas reduced levels of tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 were detected in tolerance-induced animals. Tolerance was reversed by replenishing these animals with recombinant interleukin-2. Tolerance could be adoptively transferred by removing lymph node cells from tolerance-induced donors and giving them to recipient rats. Interestingly, adoptive transfer of tolerance failed when lymph nodes cells were depleted of CD4(+)CD25(+) T cells. In conclusion, T-cell nonresponsiveness because of active suppression mediated by T-regulatory cells facilitates the development of tolerance to MAA in EAAU.
Matta
Bharati
B
Department of Ophthalmology, Jones Eye Institute, Little Rock, AR 72205, USA.
Jha
Purushottam
P
Bora
Puran S
PS
Bora
Nalini S
NS
D019264:Adoptive Transfer; D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage / Q000276:immunology* / Q000494:pharmacology; D001324:Autoantigens / Q000008:administration & dosage / Q000276:immunology* / Q000494:pharmacology; D001327:Autoimmune Diseases / Q000276:immunology* / Q000473:pathology; D015704:CD4 Antigens / Q000378:metabolism*; D002417:Cattle; D049109:Cell Proliferation / Q000187:drug effects; D018920:Coculture Techniques; D007108:Immune Tolerance / Q000187:drug effects / Q000276:immunology*; D007275:Injections, Intravenous; D007376:Interleukin-2 / Q000494:pharmacology; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism; D008198:Lymph Nodes / Q000187:drug effects / Q000473:pathology; D018655:Lymphocyte Count; D008297:Male; D051381:Rats; D011917:Rats, Inbred Lew; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects / Q000276:immunology*; D014605:Uveitis / Q000276:immunology* / Q000473:pathology
D000951:Antigens, Neoplasm; D001324:Autoantigens; D015704:CD4 Antigens; D007376:Interleukin-2; D053645:Interleukin-2 Receptor alpha Subunit; C532994:melanin-associated antigen, rat